Pharming (PHAR) Non-Current Deferred Tax Liability (2019 - 2025)

Pharming's Non-Current Deferred Tax Liability history spans 7 years, with the latest figure at -$31.0 million for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at -$31.0 million for Q4 2025, down 1.55% from a year ago — trailing twelve months through Dec 2025 was -$31.0 million (down 1.55% YoY), and the annual figure for FY2025 was -$31.0 million, down 1.55%.
  • Non-Current Deferred Tax Liability for Q4 2025 was -$31.0 million at Pharming, down from -$30.5 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of -$21.2 million in Q4 2021 to a low of -$31.0 million in Q4 2025.
  • The 5-year median for Non-Current Deferred Tax Liability is -$29.8 million (2023), against an average of -$27.1 million.
  • The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 31.45% in 2021, then dropped 29.55% in 2023.
  • Year by year, Non-Current Deferred Tax Liability stood at -$21.2 million in 2021, then dropped by 8.28% to -$23.0 million in 2022, then dropped by 29.55% to -$29.8 million in 2023, then decreased by 2.63% to -$30.5 million in 2024, then fell by 1.55% to -$31.0 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at -$31.0 million, -$30.5 million, and -$29.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.